The Dermatology Drugs Market is predicted to reach US$ by 2030 from US$ 34.56 billion in 2021, and to grow at a CAGR of 10.5% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Drug Class (Antifungal, Corticosteroids, Anti-inflammatory & Anti-pruritic, Antibacterial, and Retinoids), by Disease Indication (Acne, Psoriasis, Atopic Dermatitis, Rosacea, and Skin Cancer), by Route of Administration (Oral, Topical and Parenteral), by Distribution Channel (Retail Pharmacy, Online Pharmacy, and Hospital Pharmacy)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Merck & Co., Inc., Bausch Health Companies Inc., Botanix Pharmaceuticals, Pfizer Inc., AbbVie Inc., Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca, Galderma S.A, Bristol-Myers Squibb Company, and Amgen Inc. among others
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Dermatology Drugs - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Dermatology Drugs - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Dermatology Drugs - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Dermatology Drugs - ANALYSIS & FORECAST, BY REGION
North America Dermatology Drugs
1. North America Dermatology Drugs , by Country
1. US
2. Canada
1. North America Dermatology Drugs , by Product
2. North America Dermatology Drugs , by Type
3. North America Dermatology Drugs , by Gender
4. North America Dermatology Drugs , by Sales Channel
3. Europe Dermatology Drugs
1. Europe Dermatology Drugs , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Dermatology Drugs , by Product
3. Europe Dermatology Drugs , by Type
4. Europe Dermatology Drugs , by Gender
5. Europe Dermatology Drugs , by Sales Channel
4. Asia Pacific Dermatology Drugs
1. Asia Pacific Dermatology Drugs , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Dermatology Drugs , by product
3. Asia Pacific Dermatology Drugs , by Type
4. Asia Pacific Dermatology Drugs , by Gender
5. Asia Pacific Dermatology Drugs , by Sales Channel
5. Rest of the World Dermatology Drugs
1. Rest of the World Dermatology Drugs , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Dermatology Drugs , by Product
3. Rest of the World Dermatology Drugs , by Type
4. Rest of the World Dermatology Drugs , by Gender
5. Rest of the World Dermatology Drugs , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 70